Abstract: A novel quinoline derivative inhibitor has a structure represented by the following general formula (I). The compound may selectively inhibit the TAM?family of tyrosine kinases/and CSFIR kinase, and may be used for the treatment and/or prevention of diseases mediated by the abnormal expression of TAM family kinases/and CSFlR kinase receptors and/or ligands thereof Furthermore, the compound may be used to treat and/or prevent related diseases caused by NTRK, more specifically, the compound may be used for the treatment and/or prevention of drug-resistant related diseases caused by NTRK mutations. The definitions of each group are as shown in the description.
Abstract: Provided herein are compositions including methylene bis[4,4?-(2-chlorophenylureidophenoxyisobutyric acid)] (LR-90) or a pharmaceutically acceptable salt or derivative thereof and methods of use thereof for treating and/or preventing chemotherapy-induced neuropathic pain in a subject in need thereof.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
October 13, 2026
Assignee:
CITY OF HOPE
Inventors:
James L. Figarola, Jyotirmoy Kusari, Arthur Riggs, David Horne
Abstract: A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
Type:
Grant
Filed:
October 25, 2019
Date of Patent:
October 13, 2026
Assignee:
The Research Foundation for The State University of New York
Inventors:
Christopher Roy Bishop, Anthony West, Fredric Manfresson
Abstract: The compounds disclosed herein may be inhibitors of BRG1 (Brahma-related gene-1) and/or BRM (Brahma). The compounds or pharmaceutically acceptable salts thereof are useful for the treatment of disorders associated with an alteration in a BAF complex, e.g., a disorder associated with an alteration in one or both of the BRG1 and BRM proteins. Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
Type:
Grant
Filed:
January 29, 2020
Date of Patent:
September 22, 2026
Assignee:
FOGHORN THERAPEUTICS INC.
Inventors:
Rishi G. Vaswani, Neville John Anthony, David Simon Millan, Shawn E.R. Schiller, Kevin J. Wilson, David S. Huang
Abstract: Disclosed are small molecule inhibitors of Plek2 biological activity. The compositions and method may be utilized for treating cell proliferative diseases and disorders and other diseases and disorders, such as diseases and disorders that are characterized by Plek2 expression and/or by activation of the phosphatidylinositide 3-kinase (PI3K)/Akt pathway. Cell proliferative diseases and disorders that may be treated using the disclosed compositions and methods may include, but are not limited to, myeloproliferative neoplasms (MPNs) such as Philadelphia (Ph)-negative MPNs, and cancers such as acute myeloid leukemia (AML) and cancers characterized by solid tumors.
Abstract: A lactose free, stable pharmaceutical composition having naltrexone or its pharmaceutically acceptable salt thereof. Also disclosed is a process for the preparation of the composition and its use in a method for the treatment of Crohn's disease.
Abstract: A method for preparing biliverdin or a derivative thereof includes applying a compound represented by formula 2 as a raw material; R is hydrogen, C1-C5 alkyl, or benzyl; “” at positions A and B independently represent a single bond or a double bond; when “” represents a single bond, R1 or R2 connected to the single bond is selected from one of tosyl, p-toluenesulfonyl, phenylsulfonyl, phenylsulfinyl; and when “” represents a double bond, R1 or R2 connected to the double bond is hydrogen.
Abstract: Provided are: a composition for forming a hole transporting layer for perovskite solar cells, which is inexpensive and does not need to be used together with a dopant; and a compound which can be contained in a composition for forming a hole transporting layer.
Type:
Grant
Filed:
August 1, 2019
Date of Patent:
September 15, 2026
Assignee:
TOKYO CHEMICAL INDUSTRY CO., LTD.
Inventors:
Hidetaka Nishimura, Iku Okada, Taro Tanabe, Atsushi Wakamiya
Abstract: Novel compounds of structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of Formula I may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
Type:
Grant
Filed:
May 5, 2022
Date of Patent:
September 1, 2026
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Ashok Arasappan, Ian M. Bell, Jason M. Cox, Michael J. Kelly, III, Mark Eric Layton, Hong Liu, Jian Liu, Akshay A Shah, Michael D. VanHeyst
Abstract: Provided herein are compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in the subject. In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels. In certain embodiments, the fullerenes are polyhydroxy fullerenes (PHFs).
Abstract: The present invention relates to a co-crystal of coenzyme QH and nicotinamide, a preparation method therefor and the use thereof. Compared with the existing coenzyme QH, the co-crystal has a higher melting point and superior stability. The preparation method for the co-crystal of coenzyme QH is simple, easy to control and good in terms of reproducibility. The present invention greatly improves the use convenience of coenzyme QH, saves costs during storage, transportation and use, and broadens the application range of coenzyme QH.
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
Type:
Grant
Filed:
August 17, 2021
Date of Patent:
August 18, 2026
Assignee:
Genentech, Inc.
Inventors:
Marie-Gabrielle Braun, Joachim Rudolph, Yao Wu, Guosheng Wu
Abstract: The present disclosure provides compounds that are inhibitors of interleukin-1 receptor-associated kinases 1 and 4 (IRAK1 and IRAK4) and their use in the treatment of medical disorders such as autoimmune disorders, cancer, and pain disorders.
Type:
Grant
Filed:
July 23, 2021
Date of Patent:
August 11, 2026
Assignee:
The University of Rochester
Inventors:
Michael Becker, Rakesh Singh, Richard Moore, Laura Calvi
Abstract: The present disclosure is directed to compositions and methods for the inhibition of DNA polymerases. the compositions disclosed herein include one or more of indole-derived compounds useful in treatment of cancers including those which are resistant to genotoxic therapies.
Type:
Grant
Filed:
January 14, 2020
Date of Patent:
July 21, 2026
Inventors:
Robert Eoff, Narsimha Penthala, Peter Crooks
Abstract: A combinatorial method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site utilizing virus (IRES-utilizing virus) in a host in need of treatment involves administering the host a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: wherein each R1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo; and either separately administering another anti-viral drug and/or pro-drug to the anti-viral drug or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
July 14, 2026
Assignees:
Howard University, GEORGETOWN UNIVERSITY
Abstract: The disclosed compositions and methods relate to compositions for human consumption comprising paraxanthine and a cholinergic agent and/or theanine. The disclosed compositions are useful for promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.
Type:
Grant
Filed:
October 13, 2022
Date of Patent:
June 30, 2026
Assignee:
PX ING, LLC
Inventors:
Shawn Wells, Ralf Jager, Kylin Liao, Martin Purpura
Abstract: The present invention relates to a method of inducing mesenchymal-epithelial transition (MET) in a basal-like (or mesenchymal-like) cancer cell by contacting the cancer cell with an inducer of mesenchymal-epithelial transition for a time and under conditions sufficient to induce MET in the cell. Additionally, there is also provided a method of inhibiting epithelial-mesenchymal transition (EMT) of a cancer in a subject, the method comprising administering an inhibitor or regulator of lipid metabolism for a sufficient time and under conditions to inhibit epithelial mesenchymal transition (EMT) of the cancer in the subject.
Type:
Grant
Filed:
November 11, 2019
Date of Patent:
June 30, 2026
Assignee:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventors:
Wai Leong Tam, Ser Yue Loo, Li Ping Toh
Abstract: Optimised sulfur based pesticides using sulfosuccinates alone and in combination with an anionic surfactant to improve the retention and distribution of sulfur on plant vegetation from aqueous spray solutions.
Abstract: The present invention relates to a Crystalline Form A of a compound of Chemical Formula 1 having physically and chemically outstanding characteristics compared to amorphous forms and other crystalline forms of the compound of Chemical Formula 1. Crystalline Form A of the compound of Chemical Formula 1 according to the present invention, compared to amorphous forms or other crystalline forms, does not denature even at prolonged exposure to harsh conditions, has low water sorption, is advantageous for formulation as the crystalline form does not change even under pressure or when pulverized, and the crystalline form itself has excellent stability, being useful for storage for extended periods.
Type:
Grant
Filed:
April 11, 2022
Date of Patent:
June 9, 2026
Assignee:
MITOIMMUNE THERAPEUTICS INC.
Inventors:
Soon Ha Kim, Hye Kyung Chang, Hyoung Jin Kim, Sae Yeon Lee, Sang Kweon Jeon, Eun Kyung Yoo, Mooyoung Seo
Abstract: The present invention provides methods for treating a genetic neurodevelopmental disorder such as Rett syndrome, comprising administering to a subject in need thereof a liquid oral dosage formulation comprising a therapeutically effective amount of ANAVEX2-73.